Salute e Benessere

AWAK Transforms into Vivance, Unveiling a New Brand Identity

Suresha Venkataraya, CEO of Vivance, said, "This rebrand reflects how far we've come, and where we're heading. Building on the foundation of our wearable dialysis device, we've made significant strides by expanding our portfolio to include cost-effective home modalities and complementary digital offerings. This rebrand reinforces our ultimate mission of treating patients in the comfort of their homes." Suresha Venkataraya, CEO of Vivance, said, "This rebrand reflects how far we've…
PR Newswire
09/10/2024

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital…

Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed...
Nasdaq GlobeNewswire
09/10/2024

CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer…

Key Takeaways from the CD47 Inhibitors Market Report Key Takeaways from the CD47 Inhibitors Market Report Discover which therapies are expected to grab the CD47 inhibitors market share @ CD47 Inhibitors Market Report CD47 Inhibitors Market Dynamics The market for CD47 inhibitors is evolving rapidly as these novel therapeutics gain traction in oncology for their potential to evade the "don't eat me" signal in cancer cells, thereby enhancing the immune system's ability to eliminate…
PR Newswire
08/10/2024

Disclosure of notification received from AOC Pharma S.à r.l.

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from AOC Pharma S.à r.l. Notification by AOC Pharma S.à r.l.On 3 October 2024, Fagron received a notification that changes took place in the chain of controlled undertakings through...
Nasdaq GlobeNewswire
08/10/2024

High tech specs and adapted World Cup pitch sensors awarded share of £1.5m as…

The global challenge prize is funded by Alzheimer's Society and Innovate UK and delivered by Challenge Works (part of Nesta). The global challenge prize is funded by Alzheimer's Society and Innovate UK and delivered by Challenge Works (part of Nesta). One in three people born in the UK today will develop dementia in their lifetime, with around a million people in the UK living with a form of dementia now. This is projected to rise to 1.4 million people by 2040. The five finalists, who...
PR Newswire
08/10/2024

Healthy Buildings Market to Be Worth $71.5 Billion by 2031--Exclusive Report by…

Download FREE PDF Brochure Of Healthy Buildings Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6010 Download FREE PDF Brochure Of Healthy Buildings Market -https://www.meticulousresearch.com/download-sample-report/cp_id=6010 This market's growth is propelled by increasing awareness of air quality, occupant wellness, and mental wellbeing within building environments and rapid urbanization in emerging markets. However, the elevated costs of implementation...
PR Newswire
08/10/2024

Peripheral Vascular Devices Market to Hit USD 14.73 Billion by 2029 with 5.2%…

Browse in-depth TOC on "Peripheral Vascular Devices Market" Browse in-depth TOC on "Peripheral Vascular Devices Market" 365 - Tables 52 - Figures 323 - Pages Based on type, the Peripheral vascular devices Market is segmented into Angioplasty balloons, Angioplasty stents, Catheters, Endovascular aneurysm repair stent grafts, Inferior cava filters, Plaque modification devices, Hemodynamic flow alteration devices, and Other peripheral vascular devices. Peripheral vascular...
PR Newswire
08/10/2024

Medical Imaging Equipment Services Market Poised for Significant Growth…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1013778 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1013778 202 - Pages126 – Tables37 – Figures Scope Of The Report Medical Imaging Equipment Services Market Overview 1.Market Size and Growth ProjectionsThe global Medical Imaging Equipment Services Market is experiencing robust growth, projected to expand from approximatelyUSD 60...
PR Newswire
08/10/2024

Electrophysiology Market is expected to generate a revenue of USD 17.04 Billion…

With the increasing prevalence of cardiac arrhythmias and advancements in minimally invasive procedures, the electrophysiology market is poised for transformative growth. Our report examines key drivers, including innovations in catheter ablation, diagnostic EP devices, and real-time monitoring systems. It highlights the adoption of cutting-edge technologies, growing demand for personalized medicine, and the integration of AI-powered diagnostic tools. With the increasing prevalence of cardiac...
PR Newswire
08/10/2024

Over The Counter (OTC) Drugs Market is expected to generate a revenue of USD…

The OTC drugs market is undergoing significant expansion, driven by increased consumer demand for self-medication, easier access to pharmaceuticals, and growing awareness of personal health. The report offers a detailed examination of market drivers, such as shifting consumer behavior, regulatory updates, and the influence of e-commerce on OTC drug sales. The OTC drugs market is undergoing significant expansion, driven by increased consumer demand for self-medication, easier access to...
PR Newswire
08/10/2024

Neurolief Presents Groundbreaking Study Results of its Proliv™Rx Brain…

The summit, which brought together executives from major pharmaceutical companies and key stakeholders in psychiatric drug development, offered a forum for Neurolief to demonstrate the transformative potential of Proliv™Rx. Dr. Carpenter's presentation generated substantial interest and reflected the pharma industry's growing focus on "beyond the pill" solutions for mental health treatment. The summit, which brought together executives from major pharmaceutical companies and key…
PR Newswire
08/10/2024

SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL…

About CP-GEP (Merlin test)CP-GEP is a non-invasive prediction model for cutaneous melanoma patients that combines clinicopathologic (CP) variables with gene expression profiling (GEP). This model is able to identify cutaneous melanoma patients at low-risk for nodal metastasis who may forgo the sentinel lymph node biopsy (SLNB) procedure. The CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it has been clinically validated in multiple studies. More information (including references)…
PR Newswire
08/10/2024

Curia Commits to SBTi Net-Zero Standard

Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wide greenhouse gas (GHG) emission reductions in line with science-based net-zero with the Science Based Targets initiative (SBTi). To achieve this goal, Curia will be investing resources over the next two years to evaluate and develop GHG emission reduction targets for submission to and approval by the SBTi. “We are accountable to our community...
Nasdaq GlobeNewswire
08/10/2024

Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing…

The technology-sharing initiative aims to share Seegene's advanced diagnostic and data analysis technologies globally, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Seegene's syndromic real-time PCR technology represents a breakthrough in molecular target detection. It enables the simultaneous detection of up to 14 pathogens in a single reaction tube, with quantitative information for each target. The...
PR Newswire
08/10/2024

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed…

CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a global player in oncology, and Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision medicine, today announced that the first patient has been dosed in a Phase I/II, first-in-human dose-escalation, dose-optimization and dose-expansion trial. This clinical trial evaluates…
PR Newswire
08/10/2024

Optimum Strategic Communications to Host 16th Annual Healthcare Investor…

New to this year's event and by popular demand Optimum will be running 'Investor speed dating', bringing some of the most exciting early-stage companies together with leading investors. In addition, Optimum will be hosting a panel discussion alongside its US Partner Gilmartin Group on 'How to have a successful IPO on Nasdaq' a topic that remains close to the hearts of many industry entrepreneurs. New to this year's event and by popular demand Optimum will be running'Investor speed dating',...
PR Newswire
08/10/2024

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle…

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersenInvestigational regimen also shows more rapid slowing of neurodegeneration, as measured by neurofilamentBiogen plans to submit regulatory applications around the world for approval of the nusinersen higher dose regimenCAMBRIDGE, Mass., Oct.08, 2024(GLOBE NEWSWIRE) --Biogen Inc...
Nasdaq GlobeNewswire
08/10/2024

Healgen Scientific Receives FDA De Novo Marketing Authorization for At-Home…

The OTC Healgen Rapid Check® COVID-19/Flu A&B Antigen Test provides rapid, accurate and convenient detection of COVID-19, influenza A and influenza B infections. "Our combo test addresses a critical gap in clinical diagnostic testing by providing a reliable and user-friendly solution for individuals to test themselves at home," says Dr. Bingliang Fang, CEO of Healgen. "Early diagnosis enables faster initiation of appropriate treatment, leading to improved health outcomes and…
PR Newswire
08/10/2024

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A…

The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral cannabinoid formulation for managing the symptoms of patients suffering from neurodegenerative diseases such as ALS, Alzheimer's Disease and Parkinson's Disease.NEUROBIS is the second Phase 2 clinical trial supported by Avextra.NEUROBIS is one of the few randomised, placebo controlled,...
Nasdaq GlobeNewswire
08/10/2024

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA…

Prolia ®(denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva's proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva's robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such as oncology, immunology and respiratory medicineAnticipated decision by both agencies is expected...
Nasdaq GlobeNewswire
08/10/2024

MolecuLight Announces Groundbreaking Study on Antimicrobial Stewardship in Wound…

Dr. Serena, a dedicated advocate in the fight against antimicrobial resistance, shares his insights: "Antimicrobial resistance is a critical challenge across all areas of medicine, including wound care. Our study represents a significant advancement in tackling this issue. We discovered that using fluorescence imaging during patient assessments reduced the average number of concurrent medications prescribed—from 1.4 per patient with standard clinical examination to just 1 per patient…
PR Newswire
08/10/2024

Novo Nordisk launches new initiative to prevent childhood obesity in…

The initiative will launch in six cities across five continentsInterventions aim to increase physical activity and healthy eating among childrenThe three-year initiative comes with an investment of more than 250 million Danish kroner Bagsværd, Denmark, 8 October 2024– Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban...
Nasdaq GlobeNewswire
08/10/2024

Adcendo Announces US FDA Clearance of IND Application for Phase I/II…

Dr. Lone Ottesen, Chief Medical Officer of Adcendo, said: "uPARAP is a highly attractive target for the development of an ADC in mesenchymal cancers including soft tissue sarcoma, as it is highly overexpressed in multiple STS subtypes, has unique internalization properties and shows only very low expression in healthy tissues. The IND clearance of ADCE-D01 is an important milestone for our program and our company, and we look forward to initiating patient enrolment for this study and…
PR Newswire
08/10/2024

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy…

Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide's groundbreaking results from Phase II study Boehringer launches two Phase III studies of...
Nasdaq GlobeNewswire
08/10/2024
Altri  Comunicati